O slideshow foi denunciado.
Seu SlideShare está sendo baixado. ×

benign prostatic hyperplasia and carcinoma.pptx

Anúncio
Anúncio
Anúncio
Anúncio
Anúncio
Anúncio
Anúncio
Anúncio
Anúncio
Anúncio
Anúncio
Anúncio
Carregando em…3
×

Confira estes a seguir

1 de 30 Anúncio

Mais Conteúdo rRelacionado

Semelhante a benign prostatic hyperplasia and carcinoma.pptx (20)

Anúncio

Mais recentes (20)

benign prostatic hyperplasia and carcinoma.pptx

  1. 1. BENIGN PROSTATIC HYPERPLASIA Presented by : Adithya S MBBS , Govt Thiruvarur Medical College
  2. 2.  the prostate is an accessory gland of male reproductive system  The prostate is a pyramidal-shaped, fibromuscular glandular organ which surrounds the prostatic urethra.  Its secretions form the bulk of the seminal fluid. Its female homologue is paraurethral glands ANATOMY OF PROSTATE
  3. 3. The prostate is located in the lesser pelvis below the neck of the urinary bladder and above the urogenital diaphragm. It lies behind the lower part of the pubic symphysis and in front of the rectal ampulla. It is embraced on each side by the levator ani muscle. LOCATION
  4. 4. DIMENSIONS • Weight: 7 -16 g. • Width (at base): 4 cm. • Length: 3 cm. • Thickness: 2 cm GROSS FEATURES The prostate presents the following external features: 1. Apex. 2. Base. 3. Four surfaces (anterior, posterior and two inferolateral)
  5. 5. LOBES The prostate is divided into five lobes:  Anterior lobe (isthmus).  Posterior lobe.  Median lobe.  Two lateral lobes The median lobe is located between the urethra and two ejaculatory duct. The enlargement of this lobe in BPH is responsible for urethral obstruction
  6. 6. ZONES OF PROSTATE Histologically, there are two well-defined concentric zones separated by an ill-defined irregular fibrous layer. The zones are absent anteriorly  Outer zone: The larger outer zone is composed of long branching glands . This is a common site for carcinoma of prostate  Inner zone: The smaller inner zone is composed of outer submucosal glands. The inner zone of prostate is the common site of benign prostatic hypertrophy
  7. 7. CAPSULES OF PROSTATE The prostatic capsules are two in number in normal gland and three in number if gland is affected by benign hypertrophy of the prostate.  True capsule: It is formed by the condensation of peripheral fibrous stroma of the gland,  False capsule It is derived from the pelvic fascia. It is outside the true capsule  Surgical capsule: When the adenoma of the gland enlarges, the peripheral part of the organ becomes compressed. This compressed part of the gland is called surgical or pathological capsule
  8. 8. It is a condition of progressive enlargement of prostate gland, resulting from an increase in number and size of epithelial and stromal tissue Benign prostatic hyperplasia
  9. 9. ETIOLOGY 1. Ageing 2. Excessive accumulation of prostatic androgen 3. Family history 4. Diet increases animal fat and saturated fatty acid 5. Reduced exercise 6. alcohol consumption and smoking
  10. 10. PATHOPHYSIOLOGY Age advancement Decreased androgen levels Increased estrogen Stimulation and hyperplasia of prostate
  11. 11. SECONDARY EFFECTS OF BPH URETHRAL CHANGES Urethra gets compressed, elongated and gets converted into a narrow longitudinal slit CHANGES IN BLADDER  Trabeculations  Sacculations  Diverticuli  Stasis , infection and stone formation
  12. 12. CHANGES IN URETER AND KIDNEY  Bilateral hydronephrosis  Bilateral hydroureter  Renal failure
  13. 13. CLINICAL FEATURES
  14. 14. DIAGNOSIS Digital rectal examination: Enlarged lateral lobes can be easily felt. Rectal mucosa is free • GRADE I The prostatic lobes protrude minimally into the rectal lumen by 1-2 cm, the median sulcus is palpable. • GRADE II Prostatic lobes protrude> 2 cm but < 3 cm into the rectal lumen and the median sulcus is obliterated. • GRADE III 3--4 cm protrusion • GRADE IV > 4 cm protrusion of lobes, most of the rectal lumen is filled by the projecting prostatic lobes.
  15. 15. INVESTIGATIONS  Blood urine  Creatinine  Uroflowmetry • Normal peak flow rate: 20 ml/sec. • Doubtful peak obstruction: 10 to 15 ml/sec. • Definite peak obstruction: Less than 10 ml/sec  USG  Cystometrogram
  16. 16. TREATMENT The treatment plan depends on the cause of BPH , severity of the obstruction and patients general health condition DRUGS Finasteride acetate : It helps in prevention of hyperplasia: of the prostate. It is given for large prostates. α-adrenergic blockers: It is supposed to relax the internal sphincter for better drainage of the bladder (tamsulosin , terazosin, alfazocin) MEDICAL MANAGEMENT
  17. 17. TREATMENT INDICATIONS FOR SURGERY o Urinary retention o Frequency of micturition disturbs normal daily activities o Complications like haematuria ,hydronephrosis , prostatic diverticulosis SURGICAL MANAGEMENT
  18. 18. SURGICAL METHODS Transurethral resection of the prostate (TURP)  This is gold standard method.  A resectoscope is passed through the urethra and under vision with constant irrigation with water or glycine, the prostate is resected into multiple pieces and removed.  Haemostasis is obtained with the help of a cautery COMPLICATIONS  Incontinence  Retrograde ejaculation  Impotence  Bladder neck contracture
  19. 19. Transvesical suprapubic prostatectomy  This method is now restricted to glands more than 100 g in weight and associated with calculus  Through an extraperitoneal approach the bladder is opened, prostate is enucleated with finger, bleeding is controlled by inflating the Foley bulb with about 30 50 ml of air and by ligatures.  During the process, the prostatic urethra is also avulsed.  After about 7-10 days, a tract develops along the length of Foley catheter which heals by granulation, fibrosis and forms the future prostatic urethra.
  20. 20. Retropubic prostatectomy Done by extraperitoneal approach without opening the bladder, pushing the bladder to one side and excision of the prostate. Not done nowadays Perineal prostatectomy Newer treatments •Holmium: YAG laser. • Intraurethral stents- in men who are grossly unfit
  21. 21. CARCINOMA OF PROSTATE
  22. 22. INTRODUCTION  Carcinoma of the prostate is common after the age of 65 years.  The incidence increases with age.  In Western countries, it is the second most common type of carcinoma in males after 65 years, first being bronchogenic carcinoma.  Prostatectomy done for BPH does not give protection against development of carcinoma of prostate because during prostatectomy the outer zone is left undisturbed
  23. 23. CLINICAL FEATURES  Multiple bone pains  Acute retention of urine  Difficulty in passing urine  Painful micturition
  24. 24. • Hematogenous spread- occurs through prostatic venous plexus which communicates through the emissary veins with the bones • Bones affected in carcinoma prostate are METASTASIS 1.Thoracolumbar vertebrae 2. Pelvic bone, iliac crest 3. Femur 4. Scalp 5. Ribs
  25. 25. •Local spread Medial side spread – prostatic urethra affected Upward spread- bladder & seminal vesicle affected • Lymphatic spread - Prostatic chain of lymphatics drain into internal iliac nodes . From this group of nodes, para-aortic nodes, mediastinal nodes, followed by left supraclavicular nodes get involved.
  26. 26. TNM STAGING OF CARCINOMA PROSTATE
  27. 27. INVESTIGATIONS a) Transrectal ultrasound guided trucut biopsy b) X-ray of bones c) Prostatic acid phosphatase d) Serum alkaline phosphatase e) Prostate specific antigen f) Abdominal and transrectal USG g) CT / MRI h) Bone scan i) Gallium – 68 PSMA PET
  28. 28. TREATMENT Early malignancy (T1 or T2 , M0 ,N0) Radical prostatectomy - Radical prostatectomy involves pelvic lymphadenectomy and removal of the prostate, seminal vesicle including the distal urethral sphincter followed by anastomosis of urethra to the bladder neck. Radical radiotherapy - for prostate and pelvic nodes is given postoperatively Early prostatic malignancy with PSA > 20 nmol/ml or more and the patient is already beyond 65 to 70 years of age, surgery is not favoured. Radical radiotherapy is given
  29. 29. Late malignancy – T3 Androgen ablation- in the form of bilateral orchidectomy is done as the tumour is androgen-dependent followed by anti-androgenic measures like  Estrogens - oral Diethylstilboestrol  LHRH agonist – Leuprolide Chemotherapy  Docetaxel  Cabazitaxel Radiotherapy
  30. 30. CREDITS: This presentation template was created by Slidesgo, including icons by Flaticon, and infographics & images by Freepik THANKS! Please keep this slide for attribution

×